Active management of the third stage of labor, consisting of the administration of a uterotonic, prompt clamping and cutting of the umbilical cord, and controlled cord traction, is an internationally promoted approach to the prevention of postpartum hemorrhage. On the basis of several randomized trials, such management has been estimated to reduce the rate of postpartum hemorrhage by at least 50%. 1 Whether controlled cord traction is an independent contributor to the reduction in postpartum hemorrhage achieved with active management was the main question addressed in the five-center French study by Deneux-Tharaux et al. The answer is no-the rate of postpartum hemorrhage for the 2,005 women treated with cord traction was 9.8% compared with 10.3% for the 2,008 treated without traction (relative risk [RR] 0.95, 95% confidence interval [CI] 0.79-1.15). There were, however, benefits to cord traction, including a reduced need for manual placenta removal (4.2% compared with 6.1%, RR 0.69, 95% CI 0.53-0.90) and a lower rate of third-stage duration greater than 15 minutes (4.5% compared with 14.3%, RR 0.31, 95% CI 0.25-0.39). Additionally, women in the traction arm reported significantly less discomfort and pain. Importantly, none of the women treated with controlled cord traction experienced uterine inversion.
Bottom Line: Controlled cord traction does not reduce postpartum hemorrhage. It does, however, lessen the need for manual placenta removal, shorten the duration of the third stage of labor, and reduce maternal discomfort, and it does not cause uterine inversion.
Higher-Dose Oxytocin and Hemorrhage After Vaginal Delivery: A Randomized Controlled Trial
If atonic postpartum hemorrhage is on the rise, as the current literature, including the study by Mehrabadi et al, suggests, a logical question is whether it can be prevented by optimized preventive practices: for example, by administering a higher dose of prophylactic oxytocin as part of the management of the third stage of labor. This question was addressed previously in women undergoing cesarean delivery. In the double-blind study by Munn et al, 2 321 women undergoing cesarean delivery were randomized to either 10 or 80 units of oxytocin diluted in 500 mL of lactated Ringer's administered over 30 minutes after cord clamping. The trial suggested that there was a benefit to the higher dose of oxytocin because women in the low-dose oxytocin group were more likely to receive an additional uterotonic medication (39% compared with 19%, RR 2.1, 95% CI 1.4-3.0) . Moreover, the higher dose of oxytocin was not associated with any measured adverse effects, including hypotension. The recently published randomized, double-blinded trial by Tita et al was conducted among almost 3,000 women who had undergone vaginal delivery. They compared 10 and 80 units of oxytocin diluted in 500 mL of normal saline and infused over 1 hour after delivery of the placenta. The Tita trial did not bear out the promising results of Munn et al-80 units of oxytocin did not lower the rate of postpartum hemorrhage compared with 10 units (6% compared with 7%, RR 0.93, 95% CI 0.62-1.40).
Bottom Line: After vaginal delivery, 80 units of dilute oxytocin administered over 1 hour is no more effective than 10 units in preventing postpartum hemorrhage. Lee et al report a clinical success rate of 87%, defined as cessation of hemorrhage after one embolization session with no need for further embolization or surgery, and Poujade et al report a success rate of 92%. In the study by Lee et al, disseminated intravascular coagulation and massive transfusion were associated with embolization failure in approximately one third of cases; in the study by Pouhade et al, embolization failed in three of seven placenta accreta cases (43%). Five women (2%) in the former series died and none in the latter.
